Systemic Administration of Sclerostin Antibody Enhances Bone Morphogenetic Protein-Induced Femoral Defect Repair in a Rat Model

Conclusions:
In a critical-sized femoral defect in a rat model, local rhBMP-2 combined with systemic administration of Scl-Ab resulted in more robust healing that was stronger and more rigid than results for rhBMP-2 alone and intact nonoperative femora.

Clinical Relevance:
Our study demonstrated that combining an osteoinductive agent with a systemically administered antibody that promotes bone formation can enhance bone repair and has potential as a therapeutic regimen in humans.

Source: The Journal of Bone and Joint Surgery - November 18, 2015 Category: Orthopaedics Authors: Tinsley, B. A., Dukas, A., Pensak, M. J., Adams, D. J., Tang, A. H., Ominsky, M. S., Ke, H. Z., Lieberman, J. R. Tags: Basic Science, Trauma Scientific Articles Source Type: research